Healthcare entity
Every one of those 1 sits in a single category, regulation. Bitopertin is most often covered alongside APOLLO, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention Bitopertin, all published on February 23, 2026.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Bitopertin is most often covered alongside APOLLO, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention Bitopertin, all published on February 23, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bitopertin. Shared-story counts are live from our verified record — not editorial picks.
APOLLO Data Readout
Expected release of Phase 2 data which will support the traditional NDA filing.
FDA CRL Issued
Disc Medicine receives a Complete Response Letter for bitopertin's accelerated approval application.
Strategic Pivot
Company announces shift to traditional approval pathway for EPP indication.
Disc Medicine is shifting its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) after receiving a Complete Response Letter from the FDA. The company will now pursue a traditional approval pathway, with critical Phase 2 APOLLO trial data expected in the fourth quarter of 2026.
Source: finance.yahoo.com · tickerreport.com
Bitopertin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
